Multivariate analysis of overall and event-free survival, relapse, and treatment-related mortality, only significant factors
. | Overall survival . | . | Event-free survival . | . | Relapse probability . | . | TRM . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
. | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | ||||
At least 2 prior high-dose therapies | 2.48 (1.19-5.17) | .02 | - | - | - | - | - | - | ||||
Deletion 13 | - | - | 1.94 (1.03-3.67) | .04 | 3.28 (1.31-8.24) | .01 | - | - | ||||
Younger than 50 years of age | - | - | - | - | - | - | 0.13 (0.02-1.00) | .05 |
. | Overall survival . | . | Event-free survival . | . | Relapse probability . | . | TRM . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
. | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | ||||
At least 2 prior high-dose therapies | 2.48 (1.19-5.17) | .02 | - | - | - | - | - | - | ||||
Deletion 13 | - | - | 1.94 (1.03-3.67) | .04 | 3.28 (1.31-8.24) | .01 | - | - | ||||
Younger than 50 years of age | - | - | - | - | - | - | 0.13 (0.02-1.00) | .05 |
-indicates not significant.